8,700 Studies Reviewed. 87.0% Found Biological Effects. The Evidence is Clear.
Shield Your Body
Whole Body / General

The neuroprotective effects of baobab and black seed on the rat hippocampus exposed to a 900-MHz electromagnetic field

Bioeffects Seen

Mohamed H, Deniz OG, Kaplan S · 2024

Share:

900-MHz EMF exposure induced observable neuronal structural damage in the hippocampus, though neuron survival appeared unaffected, and herbal supplements showed potential protective properties.

Plain English Summary

Summary written for general audiences

This study examined whether baobab and black seed supplements could protect rat hippocampal neurons from damage caused by 900-MHz electromagnetic field exposure (1 hour daily for 28 days). While no significant differences in pyramidal neuron counts were found between EMF-exposed and control groups, histopathological analysis showed that EMF exposure produced adverse structural changes in neurons, and combined herbal treatment appeared to offer some protective effects.

Why This Matters

The study employed rigorous stereological methods for neuron quantification and examined multiple endpoints (neuron counts, histopathology, oxidative stress markers). The discrepancy between preserved neuron numbers but altered neuronal structure suggests EMF effects may be subtle or selective for certain cellular features rather than causing widespread neuronal death.

Exposure Information

Specific exposure levels were not quantified in this study.

Cite This Study
Mohamed H, Deniz OG, Kaplan S (2024). The neuroprotective effects of baobab and black seed on the rat hippocampus exposed to a 900-MHz electromagnetic field.
Show BibTeX
@article{mohamed_h_deniz_og_kaplan_s_ce3384,
  author = {Mohamed H and Deniz OG and Kaplan S},
  title = {The neuroprotective effects of baobab and black seed on the rat hippocampus exposed to a 900-MHz electromagnetic field},
  year = {2024},
  doi = {10.2147/JAA.S420140},
  
}
DOI: 10.2147/JAA.S420140PubMed: 38447905

Quick Questions About This Study

Dupilumab reduced the need for systemic corticosteroids by 70%, with only 12% of treated patients requiring steroids compared to 40% taking placebo. This represents a significant reduction in dependency on these powerful anti-inflammatory medications.
The most common reasons for steroid use were nasal polyps (27% placebo vs 3% dupilumab) and asthma exacerbations (9% placebo vs 2% dupilumab). Dupilumab dramatically reduced both nasal and respiratory inflammatory episodes requiring steroid intervention.
Yes, dupilumab significantly improved forced expiratory volume (FEV1), percent predicted FEV1, and asthma control scores at 24 weeks compared to placebo. These improvements occurred regardless of patients' previous asthma exacerbation history or prior steroid use.
The analysis included 337 patients with severe chronic rhinosinusitis with nasal polyps who also had coexisting asthma. This represents a significant population with dual respiratory inflammatory conditions requiring complex management approaches.
Overall, 26% of patients (88 out of 337) required on-treatment systemic corticosteroid use. However, this varied dramatically between groups, with 40% of placebo patients needing steroids compared to only 12% receiving dupilumab treatment.